Prevention of Nosocomial Infections in Neonatal Intensive Care Units

Abstract

Neonatal sepsis causes a huge burden of morbidity and mortality and includes bloodstream, urine, cerebrospinal, peritoneal, and lung infections as well as infections starting from burns and wounds, or from any other usually sterile sites. It is associated with cytokine - and biomediator-induced disorders of respiratory, hemodynamic, and metabolic processes. Neonates in the neonatal intensive care unit feature many specific risk factors for bacterial and fungal sepsis. Loss of gut commensals such as Bifidobacteria and Lactobacilli spp., as occurs with prolonged antibiotic treatments, delayed enteral feeding, or nursing in incubators, translates into proliferation of pathogenic microflora and abnormal gut colonization. Prompt diagnosis and effective treatment do not protect septic neonates form the risk of late neurodevelopmental impairment in the survivors. Thus prevention of bacterial and fungal infection is crucial in these settings of unique patients. In this view, improving neonatal management is a key step, and this includes promotion of breast-feeding and hygiene measures, adoption of a cautious central venous catheter policy, enhancement of the enteric microbiota composition with the supplementation of probiotics, and medical stewardship concerning H2 blockers with restriction of their use. Additional measures may include the use of lactoferrin, fluconazole, and nystatin and specific measures to prevent ventilator associated pneumonia.

Keywords

neonate - fluconazole - lactoferrin - sepsis - candida - infection - probiotics

• References

• 1 Manzoni P, Rizzollo S, Decembrino L , et al. Recent advances in prevention of sepsis in the premature neonates in NICU. Early Hum Dev 2011; 87 (Suppl. 01) S31-S33
• 2 Stoll BJ, Hansen NI, Adams-Chapman I , et al; National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection. JAMA 2004; 292: 2357-2365
• 3 Panigrahi P, Gewolb IH, Bamford P, Horvath K. Role of glutamine in bacterial transcytosis and epithelial cell injury. JPEN J Parenter Enteral Nutr 1997; 21: 75-80
• 4 Lacey JM, Wilmore DW. Is glutamine a conditionally essential amino acid?. Nutr Rev 1990; 48: 297-309
• 5 van den Berg A, van Elburg RM, Westerbeek EA, Twisk JW, Fetter WP. Glutamine-enriched enteral nutrition in very-low-birth-weight infants and effects on feeding tolerance and infectious morbidity: a randomized controlled trial. Am J Clin Nutr 2005; 81: 1397-1404
• 6 Poindexter BB, Ehrenkranz RA, Stoll BJ , et al; National Institute of Child Health and Human Development Neonatal Research Network. Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants. Pediatrics 2004; 113: 1209-1215
• 7 Vaughn P, Thomas P, Clark R, Neu J. Enteral glutamine supplementation and morbidity in low birth weight infants. J Pediatr 2003; 142: 662-668
• 8 Mohamad Ikram I, Quah BS, Noraida R, Djokomuljanto S, Faris Irfan CY, Van Rostenberghe H. A randomised controlled trial of glutamine-enriched neonatal parenteral nutrition in Malaysia. Singapore Med J 2011; 52: 356-360
• 9 Brocklehurst P, Farrell B, King A , et al; INIS Collaborative Group. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011; 365: 1201-1211
• 10 Shah PS, Kaufman DA. Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants. Cochrane Database Syst Rev 2009; (2) CD006449
• 11 DeJonge M, Burchfield D, Bloom B , et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 2007; 151: 260-265 , e1
• 12 Weisman LE, Thackray HM, Garcia-Prats JA , et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob Agents Chemother 2009; 53: 2879-2886
• 13 Weisman LE, Thackray HM, Steinhorn RH , et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 2011; 128: 271-279
• 14 ClinicalTrials.gov. Safety and efficacy of pagibaximab injection in very low birth weight neonates for prevention of staphylococcal sepsis. Available at: http://www.clinicaltrials.gov/ct2/show/study/NCT00646399?term=pagibaximab&rank=1&sect=X3015 . Accessed July 18, 2012
• 15 Goldman AS. Modulation of the gastrointestinal tract of infants by human milk. Interfaces and interactions. An evolutionary perspective. J Nutr 2000; 130 (2S, Suppl) 426S-431S
• 16 Shulman RJ, Schanler RJ, Lau C, Heitkemper M, Ou CN, Smith EO. Early feeding, antenatal glucocorticoids, and human milk decrease intestinal permeability in preterm infants. Pediatr Res 1998; 44: 519-523
• 17 Buccigrossi V, de Marco G, Bruzzese E , et al. Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatr Res 2007; 61: 410-414
• 18 Schanler RJ, Shulman RJ, Lau C. Feeding strategies for premature infants: beneficial outcomes of feeding fortified human milk versus preterm formula. Pediatrics 1999; 103 (6 Pt 1) 1150-1157
• 19 Schanler RJ, Lau C, Hurst NM, Smith EO. Randomized trial of donor human milk versus preterm formula as substitutes for mothers' own milk in the feeding of extremely premature infants. Pediatrics 2005; 116: 400-406
• 20 Advani S, Reich NG, Sengupta A, Gosey L, Milstone AM. Central line-associated bloodstream infection in hospitalized children with peripherally inserted central venous catheters: extending risk analyses outside the intensive care unit. Clin Infect Dis 2011; 52: 1108-1115
• 21 Golombek SG, Rohan AJ, Parvez B, Salice AL, LaGamma EF. “Proactive” management of percutaneously inserted central catheters results in decreased incidence of infection in the ELBW population. J Perinatol 2002; 22: 209-213
• 22 Taylor T, Massaro A, Williams L , et al. Effect of a dedicated percutaneously inserted central catheter team on neonatal catheter-related bloodstream infection. Adv Neonatal Care 2011; 11: 122-128
• 23 Jack T, Boehne M, Brent BE , et al. In-line filtration reduces severe complications and length of stay on pediatric intensive care unit: a prospective, randomized, controlled trial. Intensive Care Med 2012; 38: 1008-1016
• 24 Hemels MA, van den Hoogen A, Verboon-Maciolek MA, Fleer A, Krediet TG. Prevention of neonatal late-onset sepsis associated with the removal of percutaneously inserted central venous catheters in preterm infants. Pediatr Crit Care Med 2011; 12: 445-448
• 25 Hei MY, Zhang XC, Gao XY , et al. Catheter-related infection and pathogens of umbilical venous catheterization in a neonatal intensive care unit in China. Am J Perinatol 2012; 29: 107-114
• 26 Bianconi S, Gudavalli M, Sutija VG, Lopez AL, Barillas-Arias L, Ron N. Ranitidine and late-onset sepsis in the neonatal intensive care unit. J Perinat Med 2007; 35: 147-150
• 27 Terrin G, Passariello A, De Curtis M , et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 2012; 129: e40-e45
• 28 Graham III PL, Begg MD, Larson E, Della-Latta P, Allen A, Saiman L. Risk factors for late onset gram-negative sepsis in low birth weight infants hospitalized in the neonatal intensive care unit. Pediatr Infect Dis J 2006; 25: 113-117
• 29 Gänzle MG. Reutericyclin: biological activity, mode of action, and potential applications. Appl Microbiol Biotechnol 2004; 64: 326-332
• 30 Walter J, Britton RA, Roos S. Host-microbial symbiosis in the vertebrate gastrointestinal tract and the Lactobacillus reuteri paradigm. Proc Natl Acad Sci U S A 2011; 108 (Suppl. 01) 4645-4652
• 31 Ahrne S, Hagslatt ML. Effect of lactobacilli on paracellular permeability in the gut. Nutrients 2011; 3: 104-117
• 32 Grönlund MM, Arvilommi H, Kero P, Lehtonen OP, Isolauri E. Importance of intestinal colonisation in the maturation of humoral immunity in early infancy: a prospective follow up study of healthy infants aged 0–6 months. Arch Dis Child Fetal Neonatal Ed 2000; 83: F186-F192
• 33 Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010; 125: 921-930
• 34 Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2011; (3) CD005496
• 35 Manzoni P, Mostert M, Leonessa ML , et al. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric colonization by Candida species in preterm neonates: a randomized study. Clin Infect Dis 2006; 42: 1735-1742
• 36 Manzoni P, Lista G, Gallo E , et al. Routine Lactobacillus rhamnosus GG administration in VLBW infants: a retrospective, 6-year cohort study. Early Hum Dev 2011; 87 (Suppl. 01) S35-S38
• 37 Romeo MG, Romeo DM, Trovato L , et al. Role of probiotics in the prevention of the enteric colonization by Candida in preterm newborns: incidence of late-onset sepsis and neurological outcome. J Perinatol 2011; 31: 63-69
• 38 Kaufman DA, Manzoni P. Strategies to prevent invasive candidal infection in extremely preterm infants. Clin Perinatol 2010; 37: 611-628
• 39 Manzoni P, Mostert M, Jacqz-Aigrain E, Farina D. The use of fluconazole in neonatal intensive care units. Arch Dis Child 2009; 94: 983-987
• 40 Sims ME, Yoo Y, You H, Salminen C, Walther FJ. Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am J Perinatol 1988; 5: 33-36
• 41 Ozturk MA, Gunes T, Koklu E, Cetin N, Koc N. Oral nystatin prophylaxis to prevent invasive candidiasis in neonatal intensive care unit. Mycoses 2006; 49: 484-492
• 42 Ganesan K, Harigopal S, Neal T, Yoxall CW. Prophylactic oral nystatin for preterm babies under 33 weeks' gestation decreases fungal colonisation and invasive fungaemia. Arch Dis Child Fetal Neonatal Ed 2009; 94: F275-F278
• 43 Howell A, Isaacs D, Halliday R. Australasian Study Group For Neonatal Infections. Oral nystatin prophylaxis and neonatal fungal infections. Arch Dis Child Fetal Neonatal Ed 2009; 94: F429-F433
• 44 Violaris K, Carbone T, Bateman D, Olawepo O, Doraiswamy B, LaCorte M. Comparison of fluconazole and nystatin oral suspensions for prophylaxis of systemic fungal infection in very low birthweight infants. Am J Perinatol 2010; 27: 73-78
• 45 Aydemir C, Oguz SS, Dizdar EA , et al. Randomised controlled trial of prophylactic fluconazole versus nystatin for the prevention of fungal colonisation and invasive fungal infection in very low birth weight infants. Arch Dis Child Fetal Neonatal Ed 2011; 96: F164-F168
• 46 De Carolis MP, Lacerenza S, De Luca D, Bersani I, Costa S, Romagnoli C. Is neonatal antiretroviral therapy a risk factor for NEC occurrence?. Turk J Pediatr 2010; 52: 108-110
• 47 Manzoni P, Rinaldi M, Cattani S , et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009; 302: 1421-1428
• 48 Adamkin DH. Mother's milk, feeding strategies, and lactoferrin to prevent necrotizing enterocolitis. JPEN J Parenter Enteral Nutr 2012; 36 (1, Suppl) 25S-29S
• 49 Manzoni P, Mostert M, Stronati M. Lactoferrin for prevention of neonatal infections. Curr Opin Infect Dis 2011; 24: 177-182
• 50 Manzoni P, Decembrino L, Stolfi I , et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections; Italian Society of Neonatology. Lactoferrin and prevention of late-onset sepsis in the pre-term neonates. Early Hum Dev 2010; 86 (Suppl. 01) 59-61
• 51 Lupetti A, Brouwer CP, Dogterom-Ballering HE , et al. Release of calcium from intracellular stores and subsequent uptake by mitochondria are essential for the candidacidal activity of an N-terminal peptide of human lactoferrin. J Antimicrob Chemother 2004; 54: 603-608
• 52 Ward PP, Paz E, Conneely OM. Multifunctional roles of lactoferrin: a critical overview. Cell Mol Life Sci 2005; 62: 2540-2548
• 53 Manzoni P, Stolfi I, Messner H , et al; Italian Task Force for the Study and Prevention of Neonatal Fungal Infections–the Italian Society of Neonatology. Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial. Pediatrics 2012; 129: 116-123
• 54 Cordero L, Ayers LW, Miller RR, Seguin JH, Coley BD. Surveillance of ventilator-associated pneumonia in very-low-birth-weight infants. Am J Infect Control 2002; 30: 32-39
• 55 Cordero L, Sananes M, Coley B, Hogan M, Gelman M, Ayers LW. Ventilator-associated pneumonia in very low-birth-weight infants at the time of nosocomial bloodstream infection and during airway colonization with Pseudomonas aeruginosa . Am J Infect Control 2000; 28: 333-339
• 56 Apisarnthanarak A, Holzmann-Pazgal G, Hamvas A, Olsen MA, Fraser VJ. Ventilator-associated pneumonia in extremely preterm neonates in a neonatal intensive care unit: characteristics, risk factors, and outcomes. Pediatrics 2003; 112 (6 Pt 1) 1283-1289
• 57 Raymond J, Aujard Y. European Study Group. Nosocomial infections in pediatric patients: a European, multicenter prospective study. Infect Control Hosp Epidemiol 2000; 21: 260-263
• 58 Stover BH, Shulman ST, Bratcher DF, Brady MT, Levine GL, Jarvis WR. Pediatric Prevention Network. Nosocomial infection rates in US children's hospitals' neonatal and pediatric intensive care units. Am J Infect Control 2001; 29: 152-157
• 59 Garland JS. Strategies to prevent ventilator-associated pneumonia in neonates. Clin Perinatol 2010; 37: 629-643
• 60 Vendettuoli V, De Cunto A, Tana M , et al. [Pulmonary infections in preterm newborns]. Minerva Pediatr 2007; 59: 97-105
• 61 Ryan RM, Wilding GE, Wynn RJ, Welliver RC, Holm BA, Leach CL. Effect of enhanced ultraviolet germicidal irradiation in the heating ventilation and air conditioning system on ventilator-associated pneumonia in a neonatal intensive care unit. J Perinatol 2011; 31: 607-614
• 62 Christensen RD, Henry E, Baer VL , et al. A low-sodium solution for airway care: results of a multicenter trial. Respir Care 2010; 55: 1680-1685
• 63 Kitajima H, Sumida Y, Tanaka R, Yuki N, Takayama H, Fujimura M. Early administration of Bifidobacterium breve to preterm infants: randomised controlled trial. Arch Dis Child Fetal Neonatal Ed 1997; 76: F101-F107
• 64 Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli FF. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate 2002; 82: 103-108
• 65 Costalos C, Skouteri V, Gounaris A , et al. Enteral feeding of premature infants with Saccharomyces boulardii . Early Hum Dev 2003; 74: 89-96
• 66 Bin-Nun A, Bromiker R, Wilschanski M , et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005; 147: 192-196
• 67 Lin HC, Su BH, Chen AC , et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005; 115: 1-4
• 68 Stratiki Z, Costalos C, Sevastiadou S , et al. The effect of a bifidobacter supplemented bovine milk on intestinal permeability of preterm infants. Early Hum Dev 2007; 83: 575-579
• 69 Lin HC, Hsu CH, Chen HL , et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics 2008; 122: 693-700
• 70 Samanta M, Sarkar M, Ghosh P, Ghosh J, Sinha M, Chatterjee S. Prophylactic probiotics for prevention of necrotizing enterocolitis in very low birth weight newborns. J Trop Pediatr 2009; 55: 128-131
• 71 Rougé C, Piloquet H, Butel MJ , et al. Oral supplementation with probiotics in very-low-birth-weight preterm infants: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2009; 89: 1828-1835